ES2215379T3 - Composiciones perorales de levosimendan de liberacion controlada. - Google Patents

Composiciones perorales de levosimendan de liberacion controlada.

Info

Publication number
ES2215379T3
ES2215379T3 ES99916941T ES99916941T ES2215379T3 ES 2215379 T3 ES2215379 T3 ES 2215379T3 ES 99916941 T ES99916941 T ES 99916941T ES 99916941 T ES99916941 T ES 99916941T ES 2215379 T3 ES2215379 T3 ES 2215379T3
Authority
ES
Spain
Prior art keywords
levosimendan
release
composition
drug
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99916941T
Other languages
English (en)
Spanish (es)
Inventor
Ilkka Larma
Maarit Backman
Saila Antila
Lasse Lehtonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2215379(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Oyj filed Critical Orion Oyj
Application granted granted Critical
Publication of ES2215379T3 publication Critical patent/ES2215379T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
ES99916941T 1998-04-23 1999-04-23 Composiciones perorales de levosimendan de liberacion controlada. Expired - Lifetime ES2215379T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980901 1998-04-23
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia

Publications (1)

Publication Number Publication Date
ES2215379T3 true ES2215379T3 (es) 2004-10-01

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99916941T Expired - Lifetime ES2215379T3 (es) 1998-04-23 1999-04-23 Composiciones perorales de levosimendan de liberacion controlada.

Country Status (37)

Country Link
US (1) US7045147B1 (enExample)
EP (1) EP1071397B1 (enExample)
JP (2) JP4566402B2 (enExample)
KR (1) KR100960597B1 (enExample)
CN (1) CN1248691C (enExample)
AR (1) AR019096A1 (enExample)
AT (1) ATE258425T1 (enExample)
AU (1) AU756641B2 (enExample)
BG (1) BG64839B1 (enExample)
BR (1) BR9909869A (enExample)
CA (1) CA2329234C (enExample)
CO (1) CO5070607A1 (enExample)
CZ (1) CZ295194B6 (enExample)
DE (1) DE69914472T2 (enExample)
DK (1) DK1071397T3 (enExample)
EA (1) EA002829B1 (enExample)
EE (1) EE04220B1 (enExample)
ES (1) ES2215379T3 (enExample)
FI (1) FI980901A7 (enExample)
GE (1) GEP20032906B (enExample)
HR (1) HRP20000704B1 (enExample)
HU (1) HUP0101458A3 (enExample)
ID (1) ID27987A (enExample)
IL (2) IL138951A0 (enExample)
MX (1) MXPA00010367A (enExample)
NO (1) NO329809B1 (enExample)
NZ (1) NZ507453A (enExample)
PL (1) PL197447B1 (enExample)
PT (1) PT1071397E (enExample)
RS (1) RS49962B (enExample)
SI (1) SI1071397T1 (enExample)
SK (1) SK285427B6 (enExample)
TR (1) TR200003102T2 (enExample)
TW (1) TWI224507B (enExample)
UA (1) UA68376C2 (enExample)
WO (1) WO1999055305A2 (enExample)
ZA (1) ZA200005632B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
SK15542000A3 (sk) 2001-08-06
WO1999055305A2 (en) 1999-11-04
ATE258425T1 (de) 2004-02-15
GEP20032906B (en) 2003-02-25
CZ20003780A3 (en) 2001-05-16
UA68376C2 (en) 2004-08-16
TWI224507B (en) 2004-12-01
HRP20000704B1 (hr) 2009-11-30
YU63900A (sh) 2003-07-07
MXPA00010367A (es) 2002-06-04
RS49962B (sr) 2008-09-29
AU3524699A (en) 1999-11-16
SI1071397T1 (en) 2004-06-30
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
US7045147B1 (en) 2006-05-16
SK285427B6 (sk) 2007-01-04
HUP0101458A2 (hu) 2002-03-28
EP1071397B1 (en) 2004-01-28
CA2329234A1 (en) 1999-11-04
HRP20000704A2 (en) 2001-04-30
AU756641B2 (en) 2003-01-16
PL197447B1 (pl) 2008-03-31
CN1301163A (zh) 2001-06-27
NO329809B1 (no) 2010-12-20
PT1071397E (pt) 2004-06-30
JP4566402B2 (ja) 2010-10-20
ID27987A (id) 2001-05-03
CA2329234C (en) 2008-06-10
PL344078A1 (en) 2001-09-24
EE04220B1 (et) 2004-02-16
EA002829B1 (ru) 2002-10-31
FI980901A7 (fi) 1999-10-24
IL138951A (en) 2006-10-31
KR20010071172A (ko) 2001-07-28
JP2002512946A (ja) 2002-05-08
DE69914472T2 (de) 2004-11-11
BG64839B1 (bg) 2006-06-30
WO1999055305A3 (en) 1999-12-29
JP2010083900A (ja) 2010-04-15
EA200001098A1 (ru) 2001-04-23
NO20005313D0 (no) 2000-10-20
IL138951A0 (en) 2001-11-25
EE200000617A (et) 2002-06-17
BR9909869A (pt) 2000-12-19
CZ295194B6 (cs) 2005-06-15
KR100960597B1 (ko) 2010-06-07
TR200003102T2 (tr) 2001-02-21
FI980901A0 (fi) 1998-04-23
EP1071397A2 (en) 2001-01-31
HK1034032A1 (en) 2001-10-12
NZ507453A (en) 2003-02-28
NO20005313L (no) 2000-11-21
ZA200005632B (en) 2002-01-14
CO5070607A1 (es) 2001-08-28
DK1071397T3 (da) 2004-04-05
DE69914472D1 (de) 2004-03-04
CN1248691C (zh) 2006-04-05
AR019096A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
KR101432116B1 (ko) 새로운 라세카도트릴의 투여 방법
IE53543B1 (en) New oral dipyridamole preparations
WO2010075080A1 (en) A method of treating insomnia
JP2009137988A (ja) エリスロマイシン誘導体の持続放出性配合薬
CZ298634B6 (cs) Zpusob výroby galenické formy
WO2022177983A1 (en) Pharmaceutical compositions of cabozantinib
JP2020530832A (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2005508901A (ja) 活性成分を徐放する剤形
JP2010083900A (ja) レボシメンダンの制御放出経口用組成物
CN101444513B (zh) 一种头孢克洛口腔崩解片及其制备方法
US20040006072A1 (en) Sustained-release alprazolam composition
RU2690685C2 (ru) Фармацевтические композиции, содержащие алпелисиб
US20040009971A1 (en) Use of alprazolam in treatment of disorders of the central nervous system
US10849856B2 (en) Melatonin mini-tablets and method of manufacturing the same
HK1034032B (en) Controlled release peroral compositions of levosimendan
Maurer et al. Influence of critical process parameters on the release characteristics of ColoPulse tablets: a quality by design approach
PACKIARAJ FORMULATION AND EVALUATION OF CONTROLLED-RELEASE DOSAGE FORM OF CLARITHROMYCIN & PREDNISONE AS MODEL DRUGS